⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CORT News
Corcept Therapeutics Inc.
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
businesswire.com
CORT
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym ®
businesswire.com
CORT
Lifshitz Law PLLC Announces Investigations of Kyndryl Holdings, Inc. (NYSE: KD), Corcept Therapeutics, Inc. (NASDAQ: CORT), NuScale Power Corporation (NYSE: SMR), and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)
accessnewswire.com
KD
CORT
SMR
RARE
Form 8-K
sec.gov
CORT
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
businesswire.com
CORT
Form 8-K
sec.gov
CORT
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
businesswire.com
CORT
Form 8-K
sec.gov
CORT
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
businesswire.com
CORT
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
businesswire.com
CORT